Effect of Central Nervous System Metastases on Treatment Discontinuation and Survival in Older Women Receiving Trastuzumab for Metastatic Breast Cancer

Figure 1

Cumulative incidence of metastases in women with metastatic breast cancer receiving trastuzumab over 36 months. Note: Data truncated at 36 months because only 6% of the cohort was available for additional followup. Incidence rates estimated in patients who were free of the particular metastasis at baseline. See Table 2 for number at risk for each site of metastasis.